The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Defining secondary progressive multiple sclerosis
Open accessAbstract
A number of studies have been conducted with the onset of secondary progressive multiple sclerosis as an inclusion criterion or an outcome of interest. However, a standardized objective definition of secondary progressive multiple sclerosis has been lacking. The aim of this work was to evaluate the accuracy and feasibility of an objective definition for secondary progressive multiple sclerosis, to enable comparability of future research studies. Using MSBase, a large, prospectively acquired, global cohort study, we analysed the accuracy of 576 data-derived onset definitions for secondary progressive multiple sclerosis and first compared these to a consensus opinion of three neurologists. All definitions were then evaluated against 5-year disease outcomes post-assignment of secondary progressive multiple sclerosis: sustained disability, subsequent sustained progression, positive disability trajectory, and accumulation of severe disability. The five best performing definitions were further investigated for their timeliness and overall disability burden. A total of 17 356 patients were analysed. The best definition included a 3-strata progression magnitude in the absence of a relapse, confirmed after 3 months within the leading Functional System and required an Expanded Disability Status Scale step ≥4 and pyramidal score ≥2. It reached an accuracy of 87% compared to the consensus diagnosis. Seventy-eight per cent of the identified patients showed a positive disability trajectory and 70% reached significant disability after 5 years. The time until half of all patients were diagnosed was 32.6 years (95% confidence interval 32-33.6) after disease onset compared with the physicians' diagnosis at 36 (35-39) years. The identified patients experienced a greater disease burden [median annualized area under the disability-time curve 4.7 (quartiles 3.6, 6.0)] versus non-progressive patients [1.8 (1.2, 1.9)]. This objective definition of secondary progressive multiple sclerosis based on the Expanded Disability Status Scale and information about preceding relapses provides a tool for a reproducible, accurate and timely diagnosis that requires a very short confirmation period. If applied broadly, the definition has the potential to strengthen the design and improve comparability of clinical trials and observational studies in secondary progressive multiple sclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
Polman, C. H., Reingold, S. C., Edan, G., Filippi, M., Hartung, H., Kappos, L., Lublin, F. D., Metz, L. M., McFarland, H. F., O'Connor, P. W., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20703 · Cited by 5,017
Defining the clinical course of multiple sclerosis: The 2013 revisions
Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000560 · Cited by 3,177
Confavreux, C. (2003) · Brain · doi:10.1093/brain/awg081 · Cited by 996
Hohol, M. J., Orav, E. J., & Weiner, H. L. (1999) · Multiple Sclerosis Journal · doi:10.1177/135245859900500508 · Cited by 369
Disability progression in multiple sclerosis is slower than previously reported
Tremlett, H., Paty, D., & Devonshire, V. (2006) · Neurology · doi:10.1212/01.wnl.0000194259.90286.fe · Cited by 343
Onset of secondary progressive phase and long-term evolution of multiple sclerosis
Scalfari, A., Neuhaus, A., Daumer, M., Muraro, P. A., & Ebers, G. C. (2014) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-304333 · Cited by 291
New perspectives in the natural history of multiple sclerosis
Tremlett, H., Zhao, Y., Rieckmann, P., & Hutchinson, M. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e3973f · Cited by 261
Butzkueven, H., Chapman, J., Cristiano, E., Grand’Maison, F., Hoffmann, M., Izquierdo, G., Jolley, D., Kappos, L., Leist, T., Pöhlau, D., et al. (2006) · Multiple Sclerosis Journal · doi:10.1177/1352458506070775 · Cited by 245
Self-citationDefining reliable disability outcomes in multiple sclerosis
Kalincik, T., Cutter, G., Spelman, T., Jokubaitis, V., Havrdova, E., Horakova, D., Trojano, M., Izquierdo, G., Girard, M., Duquette, P., et al. (2015) · Brain · doi:10.1093/brain/awv258 · Cited by 244
Self-citationEriksson, M., Andersen, O., & Runmarker, B. (2003) · Multiple Sclerosis Journal · doi:10.1191/1352458503ms914oa · Cited by 221
Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives
Ontaneda, D., Fox, R. J., & Chataway, J. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70264-9 · Cited by 220
Goodkin, D. E., Cookfair, D., Wende, K., Bourdette, D., Pullicino, P., Scherokman, B., & Whitham, R. (1992) · Neurology · doi:10.1212/wnl.42.4.859 · Cited by 212
Sex as a determinant of relapse incidence and progressive course of multiple sclerosis
Kalincik, T., Vivek, V., Jokubaitis, V., Lechner-Scott, J., Trojano, M., Izquierdo, G., Lugaresi, A., Grand’Maison, F., Hupperts, R., Oreja-Guevara, C., et al. (2013) · Brain · doi:10.1093/brain/awt281 · Cited by 198
Self-citationRibbons, K. A., McElduff, P., Boz, C., Trojano, M., Izquierdo, G., Duquette, P., Girard, M., Grand’Maison, F., Hupperts, R., Grammond, P., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0122686 · Cited by 190
Self-citationDiagnostic uncertainty during the transition to secondary progressive multiple sclerosis
Katz Sand, I., Krieger, S., Farrell, C., & Miller, A. E. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458514521517 · Cited by 182
Disability as an outcome in MS clinical trials
Ebers, G. C., Heigenhauser, L., Daumer, M., Lederer, C., & Noseworthy, J. H. (2008) · Neurology · doi:10.1212/01.wnl.0000313034.46883.16 · Cited by 180
Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis
Kalincik, T., Horakova, D., Spelman, T., Jokubaitis, V., Trojano, M., Lugaresi, A., Izquierdo, G., Rozsa, C., Grammond, P., Alroughani, R., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24339 · Cited by 162
Self-citationAmato, M. P., Fratiglioni, L., Groppi, C., Siracusa, G., & Amaducci, L. A. (1988) · Archives of Neurology · doi:10.1001/archneur.1988.00520310052017 · Cited by 162
Self-citationLinomide in relapsing and secondary progressive MS: Part II: MRI results
Wolinsky, J. S., Narayana, P. A., Noseworthy, J. H., LUBLIN, F. D., Whitaker, J. N., Linde, A., Gjörstrup, P., & Sullivan, H. C. (2000) · Neurology · doi:10.1212/wnl.54.9.1734 · Cited by 143
Early Relapses, Onset of Progression, and Late Outcome in Multiple Sclerosis
Scalfari, A., Neuhaus, A., Däumer, M., DeLuca, G. C., Muraro, P. A., & Ebers, G. C. (2012) · JAMA Neurology · doi:10.1001/jamaneurol.2013.599 · Cited by 141
Kalincik, T., Spelman, T., Trojano, M., Duquette, P., Izquierdo, G., Grammond, P., Lugaresi, A., Hupperts, R., Cristiano, E., van Pesch, V., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063480 · Cited by 128
Self-citationTedeholm, H., Lycke, J., Skoog, B., Lisovskaja, V., Hillert, J. A., Dahle, C., Fagius, J., Fredrikson, S., Landtblom, A., Malmeström, C., et al. (2012) · Multiple Sclerosis Journal · doi:10.1177/1352458512463764 · Cited by 92
Quantification of impairment in MS: discussion of the scales in use
Amato, M. P., & Ponziani, G. (1999) · Multiple Sclerosis Journal · doi:10.1177/135245859900500404 · Cited by 67
Self-citationMeta-analysis of the placebo-treated groups in clinical trials of progressive MS
Weinshenker, B. G., Issa, M., & Baskerville, J. C. (1996) · Neurology · doi:10.1212/wnl.46.6.1613 · Cited by 64
Serial contrast-enhanced MR in patients with multiple sclerosis and varying levels of disability.
Filippi, M., Rossi, P., Campi, A., Colombo, B., Pereira, C., & Comi, G. (1997) · PubMed · Cited by 59
Treatment trials in progressive MS—current challenges and future directions
Koch, M. W., Cutter, G., Stys, P. K., Yong, V. W., & Metz, L. M. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.148 · Cited by 49
European validation of a standardized clinical description of multiple sclerosis
Amato, M. P., Grimaud, J., Achiti, I., Bartolozzi, M. L., Adeleine, P., Hartung, H.-P., Kappos, L., Thompson, A. J., Trojano, M., Vukusic, S., et al. (2004) · Journal of Neurology · doi:10.1007/s00415-004-0567-0 · Cited by 45
Self-citationLiu, C., Po, A. L. W., & Blumhardt, L. D. (1998) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.64.6.726 · Cited by 45
Liu, C., & Blumhardt, L. D. (1999) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.67.4.451 · Cited by 31
Cited by
Thompson, A. J., Baranzini, S. E., Geurts, J., Hemmer, B., & Ciccarelli, O. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30481-1 · Cited by 1,797
Kappos, L., Wolinsky, J. S., Giovannoni, G., Arnold, D. L., Wang, Q., Bernasconi, C., Model, F., Koendgen, H., Manfrini, M., Belachew, S., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1568 · Cited by 658
Multiple sclerosis: clinical aspects
Oh, J., Vidal-Jordana, A., & Montalban, X. (2018) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000622 · Cited by 620
Jakimovski, D., Bittner, S., Zivadinov, R., Morrow, S. A., Benedict, R. H., Zipp, F., & Weinstock-Guttman, B. (2024) · The Lancet · doi:10.1016/s0140-6736(23)01473-3 · Cited by 597
Brown, J. W. L., Coles, A., Horakova, D., Havrdova, E., Izquierdo, G., Prat, A., Girard, M., Duquette, P., Trojano, M., Lugaresi, A., et al. (2019) · JAMA · doi:10.1001/jama.2018.20588 · Cited by 546
Self-citation
Metadata
- Authors
- Lorscheider, J., Buzzard, K., Jokubaitis, V., Spelman, T., Havrdova, E., Horakova, D., Trojano, M., Izquierdo, G., Girard, M., Duquette, P., Prat, A., Lugaresi, A., Grand'Maison, F., Grammond, P., Hupperts, R., Alroughani, R., Sola, P., Boz, C., Pucci, E., Lechner-Scott, J., Bergamaschi, R., Oreja-Guevara, C., Iuliano, G., Van Pesch, V., Granella, F., Ramo-Tello, C., Spitaleri, D., Petersen, T., Slee, M., Verheul, F., Ampapa, R., Amato, M. P., McCombe, P., Vucic, S., Sánchez Menoyo, J. L., Cristiano, E., Barnett, M. H., Hodgkinson, S., Olascoaga, J., Saladino, M. L., Gray, O., Shaw, C., Moore, F., Butzkueven, H., Kalincik, T., & on behalf of the MSBase Study Group
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-07-07
- Volume
- 139
- Issue
- 9
- Pages
- 2395-2405
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2464491214
- Cited by
- 415
- References
- 31
- FWCI
- 15.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.